Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The injectable antiretroviral could potentially be given once every six months for HIV treatment or prevention.
Studies of islatravir are put on hold after participants experience declining CD4 and lymphocyte counts.
COVID-19, HIV vaccine and cure news, and long-acting HIV treatment and prevention topped the news again this year.
The novel HIV capsid inhibitor also shows promise for previously untreated people.
HIV treatment usually requires daily pills, but longer-acting regimens are gaining ground.
Lenacapavir shows promise for long-acting HIV treatment and prevention.
Long-acting antiretrovirals were the big news at CROI this year; now two of the most promising are joining forces.
A single dose of the HIV capsid inhibitor reduced viral load in highly treatment-experienced people.
Until now, researchers believed that the replication capsid’s main function was to hold viral genetic material.
Gilead’s HIV capsid inhibitor might need dosing only every six months
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
An early trial of Gilead’s HIV capsid inhibitor supports three-month dosing.
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.